George DJ, Ramaswamy K, Huang A, et al. - Using claims data from the Veterans Health Administration (VHA) database, researchers examined overall survival (OS) by race in men who received treatment with enzalutamide or abiraterone (novel hormonal therapy [NHT]) for chemotherapy-naïve metastatic castration-resistant PC (mCRPC).

• A total of 2,910 patients were identified (787 Black, mean 71.7 years; 2,123 White, mean 74.0 years) by diagnosis codes, evidence of surgical/medical castration, and a prescription claim for enzalutamide or abiraterone after castration from April 2014–March 2017.

• Better outcomes were recorded for black men with chemotherapy-naïve mCRPC initiating NHT when compared with similarly treated white men.